SCHEMBL14065294

SCHEMBL14065294

C=C1Sc2ccc(C)cc2N1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.62
ALDH1A1 P00352 1/20 0.62
PKM P14618 1/20 0.62
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
GFER P55789 1/20 0.43
POLB P06746 3/20 0.41
KMT2A Q03164 2/20 0.41
MAOA P21397 1/20 0.36
NOX1 Q9Y5S8 4/20 0.35
LMNA P02545 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MAPK1 P28482 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32
MEN1 O00255 1/20 0.32
ADRA2A P08913 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16079009 0.85 MAPT (0.49) MAPTALDH1A1PKMNPC1RAB9A
SCHEMBL11927569 0.84 MAOA (0.52) MAPTALDH1A1PKMNPC1RAB9A
SCHEMBL14872052 0.79 MAPT (0.60) MAPTALDH1A1PKMKMT2AMAOA
SCHEMBL12511895 0.79 MAPT (0.60) MAPTALDH1A1PKMRAB9AGFER
SCHEMBL19657873 0.79 MAPT (0.60) MAPTALDH1A1PKMKMT2AMAOA
SCHEMBL2756770 0.77 NOX1 (0.50) MAPTALDH1A1PKMNPC1RAB9A
SCHEMBL16079001 0.77 MAPT (0.57) MAPTALDH1A1PKMNPC1RAB9A
SCHEMBL13243303 0.77 MAPT (0.57) MAPTALDH1A1PKMNPC1RAB9A
SCHEMBL627989 0.76 MAOA (0.70) MAPTNPC1RAB9AGFERPOLB
SCHEMBL762766 0.74 MAOA (0.68) MAPTALDH1A1PKMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
EP-1403698-B1 Silver halide photographic light-sensitive material comprising a particular dye, a hydrazine derivate and a benzotriazole compound FUJIFILM CORP (JP) 2008-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation HSPA2, HSPBP1, HSPH1 MAPT 27/4885ALDH1A1 2288/4885PKM 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.